Coronary/Structural Heart

New Study Demonstrates Exceptional Performance With Cardiovascular Systems’ Diamondback 360® Coronary Orbital Atherectomy System (OAS) Dual Mode of Action

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a real-world optical coherence tomography (OCT) imaging study of coronary OAS patients were released at EuroPCR 2021. […]

Recardio Completes Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin

Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, announced the completion of its Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction. SAN FRANCISCO, May 19, 2021 /PRNewswire/ — The clinical study was designed to evaluate […]

VitalConnect Announces the Addition of Mobile Cardiac Telemetry Offering to Its Cardiac Monitoring Platform

MCT is added to the list of cardiac monitoring capabilities on a single platform including physiological parameter monitoring SAN JOSE, Calif.–(BUSINESS WIRE)–VitalConnect®, Inc., a leader in remote and in-hospital monitoring biosensor technology, announced today it has launched its VitalPatch RTM mobile cardiac telemetry (MCT) solution. The launch of the MCT […]

Real-World Data Confirm Excellent Results For Bicuspid Patients Treated With Edwards SAPIEN 3 TAVR

At 1 year, outcomes similar to overall cohort of patients IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced the results of a real-world study comparing outcomes for patients with bicuspid aortic stenosis (AS) who were treated with SAPIEN 3 and SAPIEN 3 Ultra Transcatheter Aortic Valve Replacement (TAVR) and […]

Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates

Data Support Continued Development of Single-course Gene Editing Therapies for Treatment of Cardiovascular Disease, Led by VERVE-101 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the publication of proof-of-concept data highlighting the company’s gene […]

Late-Breaking Data Confirm the Accuracy of the HeartFlow Planner in Modeling Post-PCI Outcomes

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc., a leader in revolutionizing precision heartcare, today announced new data demonstrating the accuracy of the HeartFlow Planner in providing modeled post-percutaneous coronary intervention (PCI) fractional flow reserve derived from computed tomography (FFRct) values, which are an important measure for understanding the effectiveness of a PCI […]

Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension

PARIS, May 19, 2021 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat difficult to treat/resistant hypertension and heart failure, announces the publication in Biomedicine & Pharmacotherapy of a new peer-reviewed scientific article […]

Clinical Data Updates On Edwards’ Transcatheter Mitral, Tricuspid Programs Presented At EuroPCR

IRVINE, Calif., May 18, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that clinical results from the company’s transcatheter mitral and tricuspid programs were presented as part of the late-breaking clinical trials at EuroPCR 2021, demonstrating positive outcomes for patients impacted by mitral or tricuspid heart valve disease. The clinical data presentations […]

Medtronic Evolut™ TAVR System Shows Strong Performance at Two Years in Low Risk Trial

EuroPCR: Low Risk Study Demonstrates Hemodynamic Advantages of Evolut™ Transcatheter Aortic Valve Replacement (TAVR) System Over Open Heart Surgery Out to Two Years DUBLIN, May 18, 2021 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial […]

Late-Breaking Registry Data at EuroPCR Congress Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates for the ACURATE neo2™ Aortic Valve System

MARLBOROUGH, Mass., May 18, 2021 /PRNewswire/ — Data presented at hotline and late-breaking trial sessions today at the EuroPCR 2021 congress demonstrated positive procedural performance, including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI), of the Boston Scientific (NYSE: BSX) ACURATE neo2™ Aortic Valve System within the investigator-initiated Early neo2 Registry1 and ITAL-neo Registry2 studies. “These real-world […]